Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics

Background: Tocilizumab is a monoclonal antibody proposed to manage cytokine release syndrome (CRS) associated with severe COVID-19. Previously published reports have shown that tocilizumab may improve the clinical outcomes of critically ill patients admitted to the ICU. However, no precise data abo...

Descripción completa

Detalles Bibliográficos
Autores principales: Elhazmi, Alyaa, Rabie, Ahmed A., Al-Omari, Awad, Mufti, Hani N., Sallam, Hend, Alshahrani, Mohammed S., Mady, Ahmed, Alghamdi, Adnan, Altalaq, Ali, Azzam, Mohamed H., Sindi, Anees, Kharaba, Ayman, Al-Aseri, Zohair A., Almekhlafi, Ghaleb A., Tashkandi, Wail, Alajmi, Saud A., Faqihi, Fahad, Alharthy, Abdulrahman, Al-Tawfiq, Jaffar A., Melibari, Rami Ghazi, Arabi, Yaseen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053430/
https://www.ncbi.nlm.nih.gov/pubmed/36983304
http://dx.doi.org/10.3390/jcm12062301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053430/
https://www.ncbi.nlm.nih.gov/pubmed/36983304
http://dx.doi.org/10.3390/jcm12062301

Ejemplares similares